Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

(RTTNews) - Santhera Pharmaceuticals reported total revenue from contracts with customers of 39.1 million Swiss francs compared to 103.4 million francs, prior year. Product sales were 14.8 million ...

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025 - Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 ...

Swiss biopharmaceutical company Santhera Pharmaceuticals has named Catherine Isted as its new chief financial officer. She replaces Andrew Smith, who is stepping down after five years and will assist ...

Santhera Pharmaceuticals, a specialty pharmaceutical company focused on rare diseases, announces an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) on the ...

Pratteln, Switzerland, March 4, 2025 – Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 and beyond. Dario Eklund, CEO of ...

Santhera has reached an agreement with health insurance funds in Germany on reimbursement of its Agamree treatment for Duchenne muscular dystrophy (DMD) that should support broad use of the drug.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AMN Healthcare Services (AMN – Research ...

I envision Chiesi as a proactive leader driving innovation and collaboration within the rare disease community. Our goal is ...